Map kinase signaling pathways and hematologic malignancies.
about
Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophagesProtein-arginine methyltransferase 1 suppresses megakaryocytic differentiation via modulation of the p38 MAPK pathway in K562 cellsEssential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesisMAPKAP kinase MK2 maintains self-renewal capacity of haematopoietic stem cellsGadd45 in the response of hematopoietic cells to genotoxic stressExpression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritisRedox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapyA new insight into viral proteins as Immunomodulatory therapeutic agents: KSHV vOX2 a homolog of human CD200 as a potent anti-inflammatory proteinFibroblast nemosis arrests growth and induces differentiation of human leukemia cellsLung injury after cigarette smoking is particle relatedMASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathwayPrimary human macrophages serve as vehicles for vaccinia virus replication and dissemination.Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells.Regulatory effects of SKAR in interferon α signaling and its role in the generation of type I IFN responses.Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.Gadd45 proteins: relevance to aging, longevity and age-related pathologies.Extracellular signal-regulated kinase (ERK) participates in the hypercapnia-induced Na,K-ATPase downregulation.Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses.Induction of hypoxia-inducible factor-1α inhibits drug-induced apoptosis in the human leukemic cell line HL-60.Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor.C-peptide and diabetic kidney disease.An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cellsInhibition of HCV 3a core gene through Silymarin and its fractions.SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancerHigh-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.Bacillus anthracis spores stimulate cytokine and chemokine innate immune responses in human alveolar macrophages through multiple mitogen-activated protein kinase pathwaysIn-situ generation of differential sensors that fingerprint kinases and the cellular response to their expressionActivity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisMyocyte enhancer factor (MEF)-2 plays essential roles in T-cell transformation associated with HTLV-1 infection by stabilizing complex between Tax and CREBp38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinasesProteins interaction network and modeling of IGVH mutational status in chronic lymphocytic leukemiaMEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825A closer look at specific therapeutic strategies in leukemia.Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
P2860
Q21296830-714D9E4A-6AC3-46F9-A8DD-07280CA2582FQ24310063-81FAC091-5D45-4106-A562-342F5889E39AQ24315357-1CF6A71F-3BC7-44AC-9229-9F7CC0C5A4DBQ24316376-6936B103-0598-4562-86A1-841993047C8CQ24600659-2DD296A1-252F-44BB-8BFB-EFC80C6376AAQ24812237-E5A8A734-4EAA-4600-AD0C-238F11815EF1Q26740191-F95DFC8A-8303-44AC-A5BB-81CC98F803ABQ26751623-062E080F-6949-4895-BDA2-450AD4EAD54FQ28258147-9C500CD2-3C55-4A8B-8593-969892977BBAQ28389025-93356BB9-5107-40C1-AC23-10999EF3BF85Q30009940-1C52AF60-5A49-4E75-AAE1-77D07ED90F38Q33743876-901BC992-9BEF-4FD1-9291-01A338410896Q33942430-AE8C1D84-8876-4EE5-8E00-D8F5E47E944BQ34025462-A72FF650-D53D-4EAF-BEFD-CB3BA9993298Q34099193-30FD6B4F-04F4-4733-AA8E-F4EE1BC0DE57Q34181572-E325D237-E5AC-4EE6-A398-131EF4145A4DQ34222845-7A570AF0-985A-4765-B696-290B51AC3985Q34252521-5A9B2946-0BCF-43EE-8B19-E88906269DE7Q34282044-38D100B6-0527-41B1-BBDD-E2F250076FD4Q34310053-52E31631-E8BD-4C8D-93D9-99FD837D48B1Q34316938-4FFC19AA-24B7-4870-9363-7AE41DB8BDCDQ34355754-EDE5A0BE-4983-486A-9790-8F879763C94CQ34372000-E70C3364-C855-413A-964C-E359C984FD80Q34384112-69856284-C7B2-4EB9-BC27-7C732C5318DFQ34540591-7DD79737-4FCE-48E7-84D8-585FEF45DFDBQ34765600-35FA7663-2B92-4C38-91FB-54CA1ECFFDC0Q34809056-354AD75A-EC06-413F-91C8-753CF08437C4Q34863399-13A0B62F-0EB8-4E7B-94A2-BC10DA9239ADQ34924515-959A05B3-4A0B-4113-A815-60D79F4EAA3BQ34975815-B08C82E8-F79B-4078-884C-56C73E63E75BQ34977161-B7A9768F-E827-4C7B-9BFE-9238E445E8EFQ35031403-0F7B5A71-CF91-4F39-924A-BA514CB95346Q35147986-89286FD1-E3B0-4DBB-BAD0-C9E0E22A5F70Q35218631-B129C25D-D90B-48DA-9306-97622B4788A8Q35349849-79E9F799-0583-4BA5-A8A9-682EA0BD3221Q35676869-82D9D311-5199-4CE2-9B4E-581EFD04056AQ35775566-B898D8BE-6B73-4FAE-9530-85BB1D5038F0Q35804449-9ED21020-E350-4DD0-9D9A-D6809F642243Q35821017-220E02C4-1F95-498E-9453-49B1F96BBAC5Q35848761-C108EF2A-4F2F-4E7E-AEE8-06698A14C7D9
P2860
Map kinase signaling pathways and hematologic malignancies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Map kinase signaling pathways and hematologic malignancies.
@ast
Map kinase signaling pathways and hematologic malignancies.
@en
type
label
Map kinase signaling pathways and hematologic malignancies.
@ast
Map kinase signaling pathways and hematologic malignancies.
@en
prefLabel
Map kinase signaling pathways and hematologic malignancies.
@ast
Map kinase signaling pathways and hematologic malignancies.
@en
P1433
P1476
Map kinase signaling pathways and hematologic malignancies.
@en
P2093
Leonidas C Platanias
P304
P356
10.1182/BLOOD-2002-12-3647
P407
P577
2003-03-06T00:00:00Z